Kevin Daly

Kevin P. Daly, MD

Cardiologist, Advanced Cardiac Therapies

Instructor in Pediatrics, Harvard Medical School

  • Contact: 617-355-6329

  • Fax: 617-734-9930

Medical Services

Specialties

  • Cardiac Transplantation
  • Heart Transplantation
  • Heart Failure
  • Ventricular Assist Devices
  • Cardiology

Departments

  • Cardiology
  • Cardiovascular Program

Programs

  • Heart Transplant Program
  • Cardiology Outpatient Services
  • Cardiomyopathy Program
  • Ventricular Assist Device (VAD) Program
To schedule an appointment: Call 617-355-6329 or Request an Appointment
Kevin Daly

Having a sick child can leave parents feeling scared and powerless. 

My goal is to help children and parents understand their illness so that they can regain some amount of control. Educating children, families, and other medical providers about heart failure is a key component of that process. We can then discuss treatment options and make the best decision for each individual child and family.


 

Why I entered medicine
Medicine is a calling. I became a doctor because I wanted to be able to help, protect and heal. Since I was a child, I been fascinated with how things work and how we can make them work better. Medicine challenges me to understand how to modify complex diseases processes with a goal of improving patient outcomes and quality of life.

Experience and Education

Education

Undergraduate Degree - Biochemical Sciences

Harvard University, 2000

Boston, MA

Medical Degree

Columbia University College of Physicians & Surgeons, 2004

New York, NY

Internship

Children’s Hospital at Montefiore, 2005

Bronx, NY

Residency - Pediatrics

Children’s Hospital at Montefiore, 2007

Bronx, NY

Fellowship - Pediatric Cardiology

Boston Children's Hospital, 2009

Boston, MA

Fellowship - Chief Fellow Pediatric Cardiology

Boston Children's Hospital, 2010

Boston, MA

Fellowship - Pediatric Cardiology, Heart Failure & Transplantation Senior Fellow

Boston Children's Hospital, 2011

Boston, MA

Certifications

  • General Pediatrics, Pediatric Cardiology

Professional History

I am a pediatric cardiologist at Boston Children’s Hospital specializing in Heart Failure & Transplantation. My clinical work is focused on the evaluation and management of children with advanced heart failure and those requiring mechanical circulatory support and/or heart transplantation. I am also a translational researcher focused on the development of biomarkers and novel imaging technologies which will allow for non-invasive diagnosis of cardiac allograft vasculopathy (CAV).

 
I am a clinical expert in the diagnosis and management of the highly sensitized pediatric heart transplant patient and those who develop antibody mediated rejection. I have published our center’s experience with peri-operative desensitization for crossmatch positive heart transplantation and utilized eculizumab (a terminal complement inhibitor) and bortezomib (a proteasome inhibitor) for the treatment of antibody mediated rejection. I am the only transplant physician in our group to perform intracardiac hemodynamics, endomyocardial biopsies, and coronary angiography in transplant patients and have expertise in the diagnosis of CAV.

I have demonstrated that VEGF-A can be used to stratify risk for development CAV in children after heart transplantation. We are planning a prospective study to determine if VEGF-A testing can safely reduce the frequency of invasive coronary angiography procedures in pediatric heart transplant recipients. In addition, I am leading a multi-center collaboration to design and perform the first randomized control trial of maintenance immunosuppression in pediatric heart transplantation. We expect this trial will support the first FDA approved indication for maintenance immunosuppression in pediatric heart transplantation.

Research

As a researcher, Dr. Daly’s interests focus on finding new, noninvasive ways to diagnose and monitor children with cardiac allograft vasculopathy (CAV). Dr. Daly is part of the Transplant Research Program


View Dr. Daly's Research Profile


Publications

Publications powered by Harvard Catalyst Profiles
  1. Daly KP. Finding the correct role for heart transplant in the treatment of hypoplastic left heart syndrome. J Heart Lung Transplant. 2016 Mar; 35(3):299-300.
  2. Kamin DS, Freiberger D, Daly KP, Oliva M, Helfand L, Haynes K, Harrison CH, Kim HB. What Is the Role of Developmental Disability in Patient Selection for Pediatric Solid Organ Transplantation? Am J Transplant. 2016 Mar; 16(3):767-72.
  3. Daly KP, Dearling JL, Seto T, Dunning P, Fahey F, Packard AB, Briscoe DM. Use of [18F]FDG Positron Emission Tomography to Monitor the Development of Cardiac Allograft Rejection. Transplantation. 2015 Sep; 99(9):e132-9.
  4. Starling RC, Stehlik J, Baran DA, Armstrong B, Stone JR, Ikle D, Morrison Y, Bridges ND, Putheti P, Strom TB, Bhasin M, Guleria I, Chandraker A, Sayegh M, Daly KP, Briscoe DM, Heeger PS. Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study. Am J Transplant. 2016 Jan; 16(1):121-36.
  5. Jacobs JP, Quintessenza JA, Karl TR, Asante-Korang A, Everett AD, Collins SB, Ramirez-Correa GA, Burns KM, Cohen M, Colan SD, Costello JM, Daly KP, Franklin RC, Fraser CD, Hill KD, Huhta JC, Kaushal S, Law YM, Lipshultz SE, Murphy AM, Pasquali SK, Payne MR, Rossano J, Shirali G, Ware SM, Xu M, Jacobs ML. Summary of the 2015 International Paediatric Heart Failure Summit of Johns Hopkins All Children's Heart Institute. Cardiol Young. 2015 Aug; 25 Suppl 2:8-30.
  6. Daly KP. Emerging science in paediatric heart transplantation: donor allocation, biomarkers, and the quest for evidence-based medicine. Cardiol Young. 2015 Aug; 25 Suppl 2:117-23.
  7. Bruneau S, Wedel J, Fakhouri F, Nakayama H, Boneschansker L, Irimia D, Daly KP, Briscoe DM. Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. Pediatr Nephrol. 2016 Jan; 31(1):41-51.
  8. Daly KP. Circulating donor-derived cell-free DNA: a true biomarker for cardiac allograft rejection? Ann Transl Med. 2015 Mar; 3(4):47.
  9. Daly KP, Chandler SF, Almond CS, Singh TP, Mah H, Milford E, Matte GS, Bastardi HJ, Mayer JE, Fynn-Thompson F, Blume ED. Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients. Pediatr Transplant. 2013 Nov; 17(7):661-9.
  10. Rhodes J, Ubeda-Tikkanen A, Clair M, Fernandes SM, Graham DA, Milliren CE, Daly KP, Mullen MP, Landzberg MJ. Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. Int J Cardiol. 2013 Oct 3; 168(3):2435-40.
  11. Show all
  12. Daly KP, Seifert ME, Chandraker A, Zurakowski D, Nohria A, Givertz MM, Karumanchi SA, Briscoe DM. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2013 Jan; 32(1):120-8.
  13. Bruneau S, Woda CB, Daly KP, Boneschansker L, Jain NG, Kochupurakkal N, Contreras AG, Seto T, Briscoe DM. Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation. Front Immunol. 2012; 3:54.
  14. Daly KP, Marshall AC, Vincent JA, Zuckerman WA, Hoffman TM, Canter CE, Blume ED, Bergersen L. Endomyocardial biopsy and selective coronary angiography are low-risk procedures in pediatric heart transplant recipients: results of a multicenter experience. J Heart Lung Transplant. 2012 Apr; 31(4):398-409.
  15. Daly KP, Chakravarti SB, Tresler M, Naftel DC, Blume ED, Dipchand AI, Almond CS. Sudden death after pediatric heart transplantation: analysis of data from the Pediatric Heart Transplant Study Group. J Heart Lung Transplant. 2011 Dec; 30(12):1395-402.
  16. Daly KP, Colan SD, Blume ED, Margossian R, Gauvreau K, Duncan C, Lehmann LE, Chen MH. Changes in echocardiographic measures of systolic and diastolic function in children 1 year after hematopoietic SCT. Bone Marrow Transplant. 2011 Dec; 46(12):1532-9.
  17. Daly K, Nandula SV, Murty VV, Nichols G. Variant translocation with a deletion of derivative (9q) in a case of Philadelphia chromosome positive (Ph +) essential thrombocythemia (ET), a variant of chronic myelogenous leukemia (CML) with a poor prognosis. Leuk Lymphoma. 2005 Dec; 46(12):1801-6.
To schedule an appointment: Call 617-355-6329 or Request an Appointment

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close